论文部分内容阅读
心肌梗塞溶栓治疗试验(TIMI)表明,rt-PA静脉内给药同链激酶静脉内给药相比,梗塞区供血冠脉的初始再通率较高。因此,rt-PA在美国已成为首选溶栓剂。当前静脉溶栓治疗的最高再通率是75％。肝素静脉内早期应用和联合溶栓治疗都未能突破此限度。这大概由于以下几个因素所致:血管壁内斑块出血致动脉粥样硬化斑块复杂化;血小板不断沉积于血栓使血栓不易溶解;
Thrombolytic therapy in myocardial infarction trial (TIMI) showed that initial intravenous administration of rt-PA compared with intravenous administration of streptokinase resulted in a higher initial recanalization rate of coronary artery in the infarcted area. Therefore, rt-PA has become the preferred thrombolytic agent in the United States. The current maximum recanalization rate for intravenous thrombolytic therapy is 75%. Intrahepatic heparin intravenous early use and combined thrombolytic therapy failed to exceed this limit. This is probably due to the following factors: plaque bleeding within the blood vessel plaque caused by atherosclerosis complicated by platelet deposition in the thrombus so that thrombosis is not easy to dissolve;